test

+|[MYC](MYC)|Tier 1 GE[@pasqualucciHypermutationMultipleProtooncogenes2001a], FE[@giallongoIdentificationCmycOncogene1983], CE[@christieCMYCTranslocation142008]|[Pasqualucci et al](papers/pasqualucciHypermutationMultipleProtooncogenes2001a)|[@dunsCharacterizationDLBCLPMBL2021b; @jalladesExomeSequencingIdentifies2017; @johnstonCmycHypermutationBurkitt1992]||

+@article{christieCMYCTranslocation142008,

+ title = {C-{{MYC}} Translocation in t(14;18) Positive Follicular Lymphoma at Presentation: {{An}} Adverse Prognostic Indicator?},

+ shorttitle = {C-{{MYC}} Translocation in t(14;18) Positive Follicular Lymphoma at Presentation},

+ author = {Christie, Lesley and Kernohan, Neil and Levison, David and Sales, Mark and Cunningham, Joan and Gillespie, Karen and Batstone, Paul and Meiklejohn, David and Goodlad, John},

+ date = {2008-03},

+ journaltitle = {Leukemia \& Lymphoma},

+ shortjournal = {Leuk Lymphoma},

+ volume = {49},

+ number = {3},

+ eprint = {18297523},

+ eprinttype = {pmid},

+ pages = {470--476},

+ issn = {1029-2403},

+ doi = {10.1080/10428190701836845},

+ abstract = {Follicular lymphoma (FL) is a common subtype of low grade B-cell non-Hodgkin lymphoma (NHL). Although this form of lymphoma often pursues an indolent course, in some cases it may behave in a more aggressive manner. Clinical and histological parameters have been shown to correlate with an adverse prognosis but a number of cytogenetic abnormalities may also be associated with aggressive disease. Although, the t(14;18) in itself does not affect outcome in cases of FL, secondary abnormalities that occur in a complex polyploid karyotype may identify cases with a poor prognosis. It is unusual to find both t(14;18) and C-MYC translocation in the same tumour; those cases in which it has been described include examples of high-grade B-cell NHL (either de novo or transformed FL) or B-cell acute lymphoblastic lymphoma. In this report, three cases of FL are described in which both t(14;18) and a C-MYC translocation were identified at presentation. We also summarize four further cases from the literature. This is a small series but one which raises the possibility that the presence of a C-MYC translocations at presentation may identify a particularly aggressive subtype of FL. Further studies are required to investigate the true incidence of this aberration, the impact on C-MYC regulation, clinical course and response to treatment.},

+ langid = {english},

+ keywords = {Aged,Chromosomes Human Pair 14,Chromosomes Human Pair 18,Chromosomes Human Pair 8,Cytogenetic Analysis,Female,Humans,Lymphoma Follicular,Male,Prognosis,Proto-Oncogene Proteins c-myc,Translocation Genetic,Treatment Outcome}

+}

+

+@article{giallongoIdentificationCmycOncogene1983,

+ title = {Identification of the C-Myc Oncogene Product in Normal and Malignant {{B}} Cells},

+ author = {Giallongo, A. and Appella, E. and Ricciardi, R. and Rovera, G. and Croce, C. M.},

+ date = {1983-10-28},

+ journaltitle = {Science (New York, N.Y.)},

+ shortjournal = {Science},

+ volume = {222},

+ number = {4622},

+ eprint = {6604943},

+ eprinttype = {pmid},

+ pages = {430--432},

+ issn = {0036-8075},

+ doi = {10.1126/science.6604943},

+ abstract = {Antiserum to a synthetic peptide corresponding to the carboxyl-terminus of the human c-myc protein immunoprecipitated a 48,000-dalton protein from a number of normal and malignant human and mouse cells. The size of the protein is consistent with the potential coding region predicted from the c-myc nucleotide sequence, and is the same for malignant cells carrying either a rearranged or an unrearranged c-myc oncogene. Because c-myc transcripts are expressed at higher levels in malignant than in normal B cells, it appears that an increased level of the c-myc protein rather than a change in the gene product is the relevant factor in determining transformation.},

+ langid = {english},

+ keywords = {B-Lymphocytes,Burkitt Lymphoma,Gene Expression Regulation,Humans,Oncogenes,Peptide Fragments,Proteins,Transformation Genetic}

+}

+